Table 3:
Cytokine release syndrome and neurotoxic adverse events by CNS stratum
| CNS-negative stratum (n=129) |
CNS-positive stratum (n=66) |
p value | |
|---|---|---|---|
| Cytokine release syndrome | ·· | ·· | 0·26 |
| 0 | 19 (15%) | 13 (20%) | ·· |
| 1 | 12 (9%) | 2 (3%) | ·· |
| 2 | 61 (47%) | 38 (58%) | ·· |
| 3 | 18 (14%) | 7 (11%) | ·· |
| 4 | 19 (15%) | 6 (9%) | ·· |
| Any neurotoxicity | ·· | ·· | 0·20 |
| 0 | 76 (59%) | 28 (41%) | ·· |
| 1 | 24 (19%) | 20 (30%) | ·· |
| 2 | 14 (11%) | 10 (15%) | ·· |
| 3 | 12 (9%) | 6 (9%) | ·· |
| 4 | 3 (2%) | 2 (3%) | ·· |
| Encephalopathy | ·· | ·· | 0·36 |
| 0 | 82 (64%) | 35 (53%) | ·· |
| 1 | 20 (16%) | 16 (24%) | ·· |
| 2 | 13 (10%) | 7 (11%) | ·· |
| 3 | 13 (10%) | 6 (10%) | ·· |
| 4 | 1 (1%) | 2 (3%) | ·· |
| Seizure | ·· | ·· | 0·71 |
| 0 | 119 (92%) | 61 (92%) | ·· |
| 1 | 1 (1%) | 0 | ·· |
| 2 | 5 (4%) | 4 (6%) | ·· |
| 3 | 1 (1%) | 1 (2%) | ·· |
| 4 | 3 (2%) | 0 | ·· |
| Vision changes | ·· | ·· | 0·023 |
| 0 | 126 (98%) | 59 (89%) | ·· |
| 1 | 2 (2%) | 6 (9%) | ·· |
| 2 | 1 (1%) | 1 (2%) | ·· |
| 3 | 0 | 0 | ·· |
| 4 | 0 | 0 | ·· |
| Speech impairment | ·· | ·· | 0·023 |
| 0 | 126 (98%) | 60 (91%) | ·· |
| 1 | 3 (2%) | 2 (3%) | ·· |
| 2 | 0 | 1 (2%) | ·· |
| 3 | 0 | 3 (5%) | ·· |
| 4 | 0 | 0 | ·· |
| Movement disorder | ·· | ·· | 0·42 |
| 0 | 124 (96%) | 6 (9%) | ·· |
| 1 | 5 (4%) | 1 (2%) | ·· |
| 2 | 0 | 3 (5%) | ·· |
| 3 | 0 | 0 | ·· |
| 4 | 0 | 0 | ·· |
| Cranial nerve disorder | ·· | ·· | 0·26 |
| 0 | 127 (98%) | 65 (98%) | ·· |
| 1 | 2 (2%) | 0 | ·· |
| 2 | 0 | 0 | ·· |
| 3 | 0 | 1 (2%) | ·· |
| 4 | 0 | 0 | ·· |
| Neurological serious adverse event | ·· | ·· | 0·75 |
| 0 | 102 (79%) | 48 (73%) | ·· |
| 1 | 1 (1%) | 1 (2%) | ·· |
| 2 | 12 (9%) | 9 (14%) | ·· |
| 3 | 11 (9%) | 6 (9%) | ·· |
| 4 | 3 (2%) | 2 (3%) | ·· |
Data are n (%). No grade 5 adverse events were reported.